During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

H.C. Wainwright lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $12 from $22 and keeps a Buy rating on the shares. The firm is ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 ...

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...

a proteasome inhibitor and an anti-CD38 antibody such as Janssen’s Darzalex (daratumumab). The overall response rate in the study was 72% and 28% of patients achieved a stringent complete response.

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) ...